Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932672 | 1.00 | KDM1A (0.44) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL29404068 | 1.00 | KDM1A (0.44) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL933161 | 1.00 | KDM1A (0.44) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL15017147 | 0.98 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL15017843 | 0.98 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL29526160 | 0.98 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL15017144 | 0.98 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL28286568 | 0.97 | KCNH2 (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL1765273 | 0.95 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Oxalic Acid SCHEMBL28871386 | 0.91 | HCAR2 (0.40) | KDM1AKDM1BMEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110283858-B | Method for preparing (S) -2- (2, 5-difluorophenyl) pyrrolidine by biocatalysis | 尚科生物医药（上海）有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-112457231-A | Racemization method of larotrytinib intermediate | 上海医药工业研究院 | 2021-03-09 | — | — | CN | claimed |
| CN-110283858-A | The method that biocatalysis prepares (S) -2- (2,5- difluorophenyl) pyrrolidines | 尚科生物医药（上海）有限公司 | 2019-09-27 | — | — | CN | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-115792026-B | Method for detecting enantiomer and diastereomer of larrotib | 安徽联创生物医药股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118109434-A | Transaminase and its application in synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118006577-A | Transaminase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117965480-A | Recombinant aminotransferase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11939320-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| CN-110283858-B | Method for preparing (S) -2- (2, 5-difluorophenyl) pyrrolidine by biocatalysis | 尚科生物医药（上海）有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-110283858-B | Method for preparing (S) -2- (2, 5-difluorophenyl) pyrrolidine by biocatalysis | 尚科生物医药（上海）有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-112457231-A | Racemization method of larotrytinib intermediate | 上海医药工业研究院 | 2021-03-09 | — | — | CN | disclosed |
| CN-112457231-A | Racemization method of larotrytinib intermediate | 上海医药工业研究院 | 2021-03-09 | — | — | CN | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| CN-112166113-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-111057729-A | (R) -2- (2, 5-difluorophenyl) pyrrolidine and preparation method and application thereof | 上海弈柯莱生物医药科技有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-110283858-A | The method that biocatalysis prepares (S) -2- (2,5- difluorophenyl) pyrrolidines | 尚科生物医药（上海）有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110283858-A | The method that biocatalysis prepares (S) -2- (2,5- difluorophenyl) pyrrolidines | 尚科生物医药（上海）有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110283858-A | The method that biocatalysis prepares (S) -2- (2,5- difluorophenyl) pyrrolidines | 尚科生物医药（上海）有限公司 | 2019-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | KDM1A 2802/4885KDM1B 2593/4885MEN1 2752/4885 |
| US-11939320-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | KDM1A 4651/4885KDM1B 4486/4885MEN1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.